Meet The Company Bringing New Treatments For Serious Eye Issues To Market

Sign up for this week’s All Access giveaway here! 

Nancy Lurker, President and CEO of EyePoint Pharmaceuticals EYPT, was a guest on Benzinga’s All Access on September 30, 2022.

EyePoint is a pharmaceutical company developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.